- Home
- Publications
- Publication Search
- Publication Details
Title
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 1, Pages 55
Publisher
MDPI AG
Online
2019-01-10
DOI
10.3390/cancers11010055
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genetics of Natural Killer Cells in Human Health, Disease, and Survival
- (2018) Peter Parham et al. Annual Review of Immunology
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor
- (2018) Alexander D. Barrow et al. CELL
- NKG2D and its ligands in cancer
- (2018) Payal Dhar et al. CURRENT OPINION IN IMMUNOLOGY
- NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
- (2018) David A. Sallman et al. HAEMATOLOGICA
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- Current strategies exploiting NK-cell therapy to treat haematologic malignancies
- (2018) Jenna K. Johnson et al. International Journal of Immunogenetics
- Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
- (2018) Yali Han et al. Journal of Hematology & Oncology
- Frontline Science: IL-18 primes murine NK cells for proliferation by promoting protein synthesis, survival, and autophagy
- (2018) Yosif El-Darawish et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
- (2018) Quirin Hammer et al. NATURE IMMUNOLOGY
- Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion
- (2018) Lyndsay Avery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
- (2018) Lucas Ferrari de Andrade et al. SCIENCE
- Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned
- (2018) Jeanette E. Boudreau et al. TRENDS IN IMMUNOLOGY
- Identification of the fungal ligand triggering cytotoxic PRR-mediated NK cell killing of Cryptococcus and Candida
- (2018) Shu Shun Li et al. Nature Communications
- NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
- (2018) David A. Sallman et al. HAEMATOLOGICA
- Adaptive Natural Killer Cells Integrate Interleukin-18 during Target-Cell Encounter
- (2018) Quirin Hammer et al. Frontiers in Immunology
- Myeloma-escape after stem cell transplantation is a consequence of T cell exhaustion and is prevented by TIGIT blockade
- (2018) Simone A. Minnie et al. BLOOD
- Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
- (2018) Michal A. Stanczak et al. JOURNAL OF CLINICAL INVESTIGATION
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- (2018) Nadine van Montfoort et al. CELL
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
- (2018) Frederike Bensch et al. NATURE MEDICINE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
- (2018) Marcus Ruscetti et al. SCIENCE
- Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells
- (2017) David H. Raulet et al. IMMUNOLOGICAL REVIEWS
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation
- (2017) Jeanette E. Boudreau et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
- (2017) Martina Molgora et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
- (2017) Zachary B. Davis et al. SEMINARS IN IMMUNOLOGY
- Tailoring Natural Killer cell immunotherapy to the tumour microenvironment
- (2017) Alexander David Barrow et al. SEMINARS IN IMMUNOLOGY
- Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer
- (2017) Jiaying Shen et al. Cell Death & Disease
- Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
- (2017) Reed Friend et al. Drug Design Development and Therapy
- Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma
- (2017) Yuanji Xu et al. Oncotarget
- Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
- (2017) Caroline Lonez et al. BMJ Open
- Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
- (2017) Jörg U. Schmohl et al. Cancer Research and Treatment
- Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
- (2017) Thornton W Thompson et al. eLife
- Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines
- (2017) Arianexys Aquino-López et al. Frontiers in Immunology
- HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
- (2017) Amy K. Erbe et al. Frontiers in Immunology
- Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma
- (2017) Sandra Weil et al. Frontiers in Immunology
- Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
- (2017) Jingyu Zhang et al. Science Advances
- Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
- (2017) Stefanie Aust et al. Scientific Reports
- Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
- (2016) Dhifaf Sarhan et al. CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- SLAM family receptors in normal immunity and immune pathologies
- (2016) Ning Wu et al. CURRENT OPINION IN IMMUNOLOGY
- KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma
- (2016) Christopher J. Forlenza et al. JOURNAL OF CLINICAL ONCOLOGY
- NKG2D–NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo
- (2016) Saravanan Raju et al. JOURNAL OF IMMUNOLOGY
- CIS is a potent checkpoint in NK cell–mediated tumor immunity
- (2016) Rebecca B Delconte et al. NATURE IMMUNOLOGY
- Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities
- (2016) J.-Y. Shao et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
- (2016) L. Galluzzi et al. Cancer Immunology Research
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors
- (2015) S. Lu et al. CLINICAL CANCER RESEARCH
- The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8+ T Cells in Response to a Lethal Poxvirus Infection
- (2015) Aaron S. Rapaport et al. IMMUNITY
- Selection, tuning, and adaptation in mouse NK cell education
- (2015) Nadir Kadri et al. IMMUNOLOGICAL REVIEWS
- Co-evolution of MHC class I and variable NK cell receptors in placental mammals
- (2015) Lisbeth A. Guethlein et al. IMMUNOLOGICAL REVIEWS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
- (2015) F Cichocki et al. LEUKEMIA
- IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction
- (2015) Claudia A Nold-Petry et al. NATURE IMMUNOLOGY
- Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation
- (2015) Xiaodi Su et al. NATURE IMMUNOLOGY
- The prognostic landscape of genes and infiltrating immune cells across human cancers
- (2015) Andrew J Gentles et al. NATURE MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
- (2015) W. Deng et al. SCIENCE
- Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells
- (2015) J. U. Schmohl et al. Targeted Oncology
- NKG2D Receptor and Its Ligands in Host Defense
- (2015) L. L. Lanier Cancer Immunology Research
- CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
- (2014) M. K. Gleason et al. BLOOD
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- NKG2D CARs as Cell Therapy for Cancer
- (2014) Charles L. Sentman et al. CANCER JOURNAL
- Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance
- (2014) Camilla Jandus et al. JOURNAL OF CLINICAL INVESTIGATION
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Correction: Cellular Expression, Trafficking, and Function of Two Isoforms of Human ULBP5/RAET1G
- (2014) Robert A. Eagle et al. PLoS One
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Reversal of natural killer cell exhaustion by TIM-3 blockade
- (2014) Anne Gallois et al. OncoImmunology
- Regulation of Ligands for the NKG2D Activating Receptor
- (2013) David H. Raulet et al. Annual Review of Immunology
- NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
- (2013) R. Romee et al. BLOOD
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
- (2013) Y.-H. Chang et al. CANCER RESEARCH
- Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy
- (2013) Q. Zhou et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- ASC Controls IFN- Levels in an IL-18-Dependent Manner in Caspase-1-Deficient Mice Infected with Francisella novicida
- (2013) R. Pierini et al. JOURNAL OF IMMUNOLOGY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- TIM-3 Does Not Act as a Receptor for Galectin-9
- (2013) Judith Leitner et al. PLoS Pathogens
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
- (2012) Nidale Tarek et al. JOURNAL OF CLINICAL INVESTIGATION
- Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice
- (2012) Helge Frebel et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inhibitory Receptors on Lymphocytes: Insights from Infections
- (2012) P. M. Odorizzi et al. JOURNAL OF IMMUNOLOGY
- Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
- (2012) M. K. Gleason et al. MOLECULAR CANCER THERAPEUTICS
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
- (2012) Manu Rangachari et al. NATURE MEDICINE
- CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
- (2012) Rebecca Waitz et al. OncoImmunology
- Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the c cytokines and TGF- 1
- (2011) Y. P. Park et al. BLOOD
- Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models
- (2011) M. T. S. Bertilaccio et al. BLOOD
- Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
- (2011) B. Foley et al. BLOOD
- A Structural Basis for Antigen Presentation by the MHC Class Ib Molecule, Qa-1
- (2011) L. Zeng et al. JOURNAL OF IMMUNOLOGY
- Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
- (2011) J. Lee et al. MOLECULAR AND CELLULAR BIOLOGY
- Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
- (2011) S. Lopez-Verges et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
- (2010) Jennifer A. Belisle et al. Molecular Cancer
- An six-amino acid motif in the α3 domain of MICA is the cancer therapeutic target to inhibit shedding
- (2009) Xuanjun Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation
- (2009) J. Yu et al. BLOOD
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
- (2009) R. W. McGilvray et al. CLINICAL CANCER RESEARCH
- Comparative genomics indicates the mammalian CD33rSiglec locus evolved by an ancient large-scale inverse duplication and suggests all Siglecs share a common ancestral region
- (2009) Huan Cao et al. IMMUNOGENETICS
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lack of CD200 Enhances Pathological T Cell Responses during Influenza Infection
- (2009) T. P. Rygiel et al. JOURNAL OF IMMUNOLOGY
- The Essential Role of Single Ig IL-1 Receptor-Related Molecule/Toll IL-1R8 in Regulation of Th2 Immune Response
- (2009) K. Bulek et al. JOURNAL OF IMMUNOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
- (2008) A. Soriani et al. BLOOD
- TNFR1 Signaling and IFN-γ Signaling Determine whether T Cells Induce Tumor Dormancy or Promote Multistage Carcinogenesis
- (2008) Nele Müller-Hermelink et al. CANCER CELL
- Fc RIIIa Expression Is Not Increased on Natural Killer Cells Expressing the Fc RIIIa-158V Allotype
- (2008) N. Congy-Jolivet et al. CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- SIGLEC16encodes a DAP12-associated receptor expressed in macrophages that evolved from its inhibitory counterpartSIGLEC11and has functional and non-functional alleles in humans
- (2008) Huan Cao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma
- (2008) Amorette Barber et al. EXPERIMENTAL HEMATOLOGY
- Four novel ULBP splice variants are ligands for human NKG2D
- (2008) Wei Cao et al. INTERNATIONAL IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started